Clinical Events after Deferral of LAD Treatment Guided by FFR or iFR

iFR is a safe alternative for lesion deferral even when it comes to the left anterior descending artery (LAD). What is more, patients deferred with iFR showed significantly fewer events than patients deferred using FFR.

La performance diagnóstica del iFR hace temblar al FFRNeither clinical cardiologists nor interventionists feel comfortable deferring LAD treatment, because it is often perceived as high risk. If functional assessment is non-significant, they will look for an excuse to perform IVUS or any other thing to end up treating a lesion that, despite the angiography, is not ischemic.

 

Using the DEFINE-FLAIR (Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularization) the authors describe when lesions are differed using invasive functional assessment using either fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR).


Read also: How long should we wait with asymptomatic aortic stenosis and preserved LVEF?


Combined major events rate (MACE) was compared at one year between patients whose LAD lesions had been deferred using FFR vs iFR. MACE was defined as a combination of cardiovascular death, acute myocardial infarction and unplanned revascularization. Both patients and physicians in charge of follow up were blinded to whether the decision was made based on FFR or iFR.

 

In all, 872 patients had angiographic LAD lesions: 421 guided by FFR and 451 guided by por iFR were deferred.


Read also: Safety in Abdominal Aortic Aneurysm Surveillance Programs.


Events rate was significantly lower when using iFR compared against FFR (2.44% vs. 5.26%; HR: 0.46; CI 95%: 0.22 to 0.95; p=0.04). This was driven by significantly lower unplanned revascularization with iFR (2.22% iFR vs. 4.99% FFR, p=0.03) and lower infarction rate, non-significant, not numerically though (0.44% iFR vs. 2.14% FFR, p=0.06).

 

Original Title: Clinical Events After Deferral of LAD Revascularization Following Physiological Coronary Assessment.

Reference: Sayan Sen et al. J Am Coll Cardiol 2019;73:444–53.

 

444-abierto.full


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....